TIDMSN.
RNS Number : 5735U
Smith & Nephew Plc
01 April 2019
Smith & Nephew acquires developer of unique pressure injury
prevention device, Leaf Healthcare, Inc.
1 April 2019
Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical
technology business, today announces that it has agreed to acquire
Leaf Healthcare, Inc, the developer of the unique Leaf Patient
Monitoring System for pressure injury prevention and patient
mobility monitoring. The transaction follows Smith & Nephew's
successful two-year partnership with Leaf Healthcare as an
exclusive distributor and strategic investor.
The Leaf Patient Monitoring System is comprised of a small,
lightweight, wearable sensor that wirelessly monitors a patient's
position and their mobility whilst in a hospital. The tracking data
is used to automate and document the compliance with prescribed
turn protocols for patients at risk for pressure injuries.
An estimated 2.5 million pressure injuries are treated each year
in US acute care facilities alone(1) , with an estimated annual
burden of $11 billion in the United States(2) . National Pressure
Ulcer Advisory Panel (NPUAP) guidelines recommend a prevention
protocol for high-risk patients that includes prophylactic foam
dressings, preventative skin care including pH balanced skin
cleanser, and patient repositioning with early mobilisation(3) .
The Leaf Patient Monitoring System together with Smith &
Nephew's ALLEVYN LIFE and ALLEVYN GENTLE BORDER and SECURA Skin
Care products provide a comprehensive portfolio to help customers
achieve and optimise pressure injury prevention protocols.
In January 2018, an independently conducted Randomized
Controlled Trial (RCT) from Stanford University evaluated optimal
patient repositioning and found that the Leaf Patient Monitoring
System induced a 43% relative increase in turning protocol
compliance in high-risk patients. Patients treated with the Leaf
sensor were 73% less likely to develop a pressure injury(4) .
"Consistent with our initial strategic investment, Smith &
Nephew is focused on providing not just products to treat
conditions, but also supporting clinicians with technologies
designed for prevention as well as treatment, and helping
healthcare facilities reduce the cost of care," said Simon
Fraser,
President of Advanced Wound Management, Smith & Nephew. "The
Leaf Patient Monitoring System is highly complementary to Smith
& Nephew's existing wound portfolio and we are excited by the
opportunities of expanding this product within our global
portfolio."
"The benefits of patient turning and improved patient mobility
are well recognised, including the potential for shorter hospital
stays," said Barrett Larson, MD, Co-Founder and Chief Executive
Officer, Leaf Healthcare. "We are proud of the impact our
technology has already made through our existing relationship with
Smith & Nephew. We are excited by this new opportunity to
deploy our award-winning pressure injury prevention technology
through Smith & Nephew's extensive Advanced Wound Management
portfolio."
The transaction is expected to close in Q2 2019, subject to the
satisfaction of customary conditions, and will be financed from
existing cash and debt facilities. The commercial terms have not
been disclosed.
1 Reddy M, Gill SS, Rochon PA. Preventing pressure ulcers: a
systematic review. Jama. 2006;296:974-84.
2 Russo et el. Hospitalizations Related to Pressure Ulcers,
2006. HCUP Statistical Brief #64. December 2008. Agency for
Healthcare Research and Quality, Rockville, MD.
(3) National Pressure Ulcer Advisory Panel, European Pressure
Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance.
Prevention and Treatment of Pressure Ulcers: Quick Reference Guide.
Emily Haesler (Ed.). Cambridge Media: Osborne Park, Australia;
2014
(4) Pickham D, Berte N, Pihulic M, Valdez A, Barbara M, Desai M.
Effect of a wearable patient sensor on care delivery for preventing
pressure injuries in acutely ill adults: A pragmatic randomized
clinical trial (LS-HAPI study). Int J Nurs Stud. 2018; 80,
12-19.
Enquiries
Investors
Andrew Swift, Smith & Nephew +44 (0) 20 7960 2285
Media
Charles Reynolds, Smith & Nephew +44 (0) 1923 477314
Ben Atwell/ Andrew Ward, FTI Strategic Consulting +44 (0) 20 3727 1000
About Smith & Nephew
Smith & Nephew is a portfolio medical technology business
with leadership positions in Orthopaedics, Advanced Wound
Management and Sports Medicine. Smith & Nephew has more than
16,000 employees and a presence in more than 100 countries. Annual
sales in 2018 were $4.9 billion. Smith & Nephew is a member of
the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
corporate website www.smith-nephew.com and follow us on Twitter,
LinkedIn or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACQDBLBXKXFZBBD
(END) Dow Jones Newswires
April 01, 2019 04:00 ET (08:00 GMT)
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Apr 2024 to May 2024
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From May 2023 to May 2024